Difference between revisions of "Antiphospholipid antibody syndrome"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Tag: visualeditor
Line 1: Line 1:
 
{| class="wikitable" style="text-align:center; width:100%;" {|
 
{| class="wikitable" style="text-align:center; width:100%;" {|
−
! colspan="4" align="center" style="color:white; font-size:125%; background-color:#31a354" |'''Section editors'''
+
! colspan="4" style="color:white; font-size:125%; background-color:#31a354" align="center" |'''Section editors'''
 
|-
 
|-
 
| style="background-color:#F0F0F0; width:15%" |[[File:Shruti.jpg|frameless|upright=0.3|center]]
 
| style="background-color:#F0F0F0; width:15%" |[[File:Shruti.jpg|frameless|upright=0.3|center]]
Line 24: Line 24:
 
===Regimen {{#subobject:3eda79|Variant=1}}===
 
===Regimen {{#subobject:3eda79|Variant=1}}===
 
{| class="wikitable" style="width: 100%; text-align:center;"  
 
{| class="wikitable" style="width: 100%; text-align:center;"  
−
!style="width: 25%"|Study
+
! style="width: 25%" |Study
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
−
!style="width: 25%"|Comparator
+
! style="width: 25%" |Comparator
−
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+
! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 
|-
 
|-
 
|[https://www.nejm.org/doi/full/10.1056/NEJMoa035241 Crowther et al. 2003]
 
|[https://www.nejm.org/doi/full/10.1056/NEJMoa035241 Crowther et al. 2003]
Line 34: Line 34:
 
| style="background-color:#ffffbf" |Seems not superior
 
| style="background-color:#ffffbf" |Seems not superior
 
|-
 
|-
−
|[http://www.bloodjournal.org/content/early/2018/07/12/blood-2018-04-848333.long Pengo et al. 2018]
+
|[http://www.bloodjournal.org/content/early/2018/07/12/blood-2018-04-848333.long Pengo et al. 2018 (TRAPS)]  
 
| style="background-color:#1a9851" |Phase III (C)
 
| style="background-color:#1a9851" |Phase III (C)
 
|Rivaroxaban
 
|Rivaroxaban
Line 46: Line 46:
 
===References===
 
===References===
 
# Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8. Erratum in: N Engl J Med. 2004 Jul 8;351(2):200. N Engl J Med. 2003 Dec 25;349(26):2577. [https://www.nejm.org/doi/full/10.1056/NEJMoa035241 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/13679527 PubMed]
 
# Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8. Erratum in: N Engl J Med. 2004 Jul 8;351(2):200. N Engl J Med. 2003 Dec 25;349(26):2577. [https://www.nejm.org/doi/full/10.1056/NEJMoa035241 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/13679527 PubMed]
−
# Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffattia A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. Epub 2018 Jul 12. [Epub ahead of print] [http://www.bloodjournal.org/content/early/2018/07/12/blood-2018-04-848333.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30002145 PubMed]  
+
# Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffattia A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. Epub 2018 Jul 12. [Epub ahead of print] [http://www.bloodjournal.org/content/early/2018/07/12/blood-2018-04-848333.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30002145 PubMed]
  
 +
== Rivaroxaban monotherapy ==
 +
 +
=== Regimen ===
 +
{| class="wikitable"
 +
!Study
 +
!Evidence
 +
!Comparator
 +
!Efficacy
 +
|-
 +
|[http://www.bloodjournal.org/content/early/2018/07/12/blood-2018-04-848333.long Pengo et al. 2018 (TRAPS)]
 +
|Phase III (C)
 +
|Warfarin
 +
|
 +
|-
 +
|
 +
|
 +
|
 +
|
 +
|-
 +
|
 +
|
 +
|
 +
|
 +
|}
 +
''Note: Pengo et al. 2018 was closed prematurely due to excess events in the rivaroxaban arm.''
 +
 +
==== Therapy ====
 +
* Rivaroxaban (Xarelto) PO
 +
Continued indefinitely
 +
 +
References
 +
# Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffattia A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. Epub 2018 Jul 12. [Epub ahead of print] [http://www.bloodjournal.org/content/early/2018/07/12/blood-2018-04-848333.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30002145 PubMed]
 
[[Category:Antiphospholipid antibody syndrome regimens]]
 
[[Category:Antiphospholipid antibody syndrome regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Autoimmune hematologic conditions]]
 
[[Category:Autoimmune hematologic conditions]]
 
[[Category:Thrombotic disorders]]
 
[[Category:Thrombotic disorders]]

Revision as of 02:59, 10 September 2018

Section editors
Shruti.jpg
 Shruti Chaturvedi, MBBS, MSCI
Baltimore, MD
LinkedIn
Tillman Benjamin-2.jpg
 Benjamin Tillman, MD
Nashville, TN
1 regimens on this page
1 variants on this page


Guidelines

To be completed

All lines of therapy

Warfarin monotherapy

back to top

Regimen

Study Evidence Comparator Efficacy
Crowther et al. 2003 Phase III (C) High-intensity Warfarin (INR 3.1 to 4.0) Seems not superior
Pengo et al. 2018 (TRAPS) Phase III (C) Rivaroxaban Fewer events

Note: Pengo et al. 2018 was closed prematurely due to excess events in the rivaroxaban arm.

Therapy

Continued indefinitely

References

  1. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8. Erratum in: N Engl J Med. 2004 Jul 8;351(2):200. N Engl J Med. 2003 Dec 25;349(26):2577. link to original article PubMed
  2. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffattia A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. Epub 2018 Jul 12. [Epub ahead of print] link to original article PubMed

Rivaroxaban monotherapy

Regimen

Study Evidence Comparator Efficacy
Pengo et al. 2018 (TRAPS) Phase III (C) Warfarin

Note: Pengo et al. 2018 was closed prematurely due to excess events in the rivaroxaban arm.

Therapy

  • Rivaroxaban (Xarelto) PO

Continued indefinitely

References

  1. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffattia A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. Epub 2018 Jul 12. [Epub ahead of print] link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Antiphospholipid_antibody_syndrome&oldid=31234"